GPC3/Mesothelin-CAR-γδT Cells Against Cancers

Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Study ID
NCT06196294
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Cell therapy for solid tumors — BIOLOGICAL
    Transfer γδT cells into patients for anti-ancer therapy.

Study Details

The third generation of GPC3/mesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-γδT cells for immunotherapy of human cancer patients with GPC3 or Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin-CAR-γδT cell immunotherapy on human cancers will firstly be evaluated.

Key Dates

First listed
Jan 9, 2024
Start date
May 10, 2024
Status verified
Jun 2024
Primary completion
Nov 30, 2030
Completion
Dec 30, 2036

Study Design

Enrollment
30 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: γδT cell therapy for solid tumor
  • Experimental: CAR-γδT cell therapy for solid tumor

Primary Outcome Measure

Number of Patients with Dose Limiting Toxicity [ Time Frame: Six months ]

Central Contacts

Find similar trials

Nationwide
Liver cancer trialsLung cancer trialsOncology trialsGI oncology trialsHepatology trialsLung oncology trialsLung disease trials

Related Studies